1. Introduction
===============

Fragility fractures are the most concerning presentation of osteoporosis (OP) and are a signal for increased refracture risk^\[[@R1]--[@R4]\]^ and increased mortality risk^\[[@R5]\]^ particularly after a hip fracture.^\[[@R6]\]^ Systematic reviews confirm the efficacy of bone-sparing medication (medication commonly used to treat OP) in reducing the risk of future fractures^\[[@R7],[@R8]\]^ and have been integrated into clinical practice guidelines and position papers in Canada^\[[@R9],[@R10]\]^ and abroad^\[[@R11]--[@R14]\]^ that recommend fracture-risk assessment and, when indicated, bone-sparing medication for the post-fragility fracture population. Despite this agreement, \<20% of fragility fracture patients undergo testing or receive bone-sparing medication after their fragility fracture.^\[[@R15],[@R16]\]^ Post-fracture programs have emerged to address this gap, with those using dedicated coordinators to facilitate guideline uptake having the best impact.^\[[@R17]--[@R20]\]^ Results from randomized trials support this model for testing and treatment after hip^\[[@R21]\]^ and wrist fractures^\[[@R22],[@R23]\]^ with Morrish demonstrating a dose-response relationship between the intensity of the coordinator\'s role and testing and OP outcomes.^\[[@R24]\]^ Program evaluations have suggested reduced refracture rates with these program^\[[@R25],[@R26]\]^ and even reduced mortality, attributing this to the initiation of proven bone-sparing medication.^\[[@R27]\]^ Even with the cost of a dedicated coordinator, the programs are cost-effective because of the costly hip fractures prevented^\[[@R28]--[@R30]\]^: the mean attributable direct health care costs for a hip fracture range from \$36,929 (women) to \$39,479 (men) in the first year.^\[[@R31]\]^

Despite testing the benefit of a coordinator in clinical trials and implementation in various forms,^\[[@R14],[@R32]\]^ we were unable to find studies that rigorously evaluated the relative effectiveness of a coordinator-based screening or liaison program versus usual care (no coordinator in place) in a wide-scale implementation of the model while attempting to control for risk of bias, or secular trends. In Ontario (population 13.8 million), a coordinator-based screening program was initiated in 2007 as part of a broader Ontario Osteoporosis Strategy.^\[[@R33]\]^ Twenty coordinators were placed in 37 hospitals that had higher volumes of these fragility fractures, and offered orthopedically managed outpatient fracture clinics. Another 23 similar hospitals existed at the time but were not assigned a coordinator due to budget limits (control hospitals in our analysis). All hospitals had orthopedic services and handled moderate-to-higher volumes of fracture patients. Hospitals chosen for a coordinator were selected based on the ability to integrate a coordinator into their post-fracture care, and proximity to another hospital site to allow sharing of a coordinator within a reasonable distance. Each hospital was approached by the Ministry of Health\'s delegate regarding participating in the program and hospital-specific agreements were negotiated for the coordinator and their role. The coordinator\'s role is to identify fragility fracture patients (defined as over 50 years of age with a low-trauma fracture) usually by case finding in the fracture clinic, and to facilitate investigation and interventions through the patient\'s primary care provider (PCP). At the control hospitals, no specific additions were made to the fracture management program and any care was dependent on the initiative of the usual health care team and their practices.

The purpose of our study was to evaluate the impact of the implementation of the Fracture Clinic Screening Program (FCSP) of the Ontario Osteoporosis Strategy on bone mineral density (BMD) testing, medication initiation, and medication persistence in the year after a fragility fracture.

2. Methods
==========

2.1. Fracture Clinic Screening Program
--------------------------------------

The FCSP was started in January 2007 to case find (identify) fragility fracture patients (age 50 or over, and low energy fractures, that is, fractures due to slips, trips, or falls from standing height or less), to offer education to the patient and their PCP, to offer advice, and recommendations on testing needed for fracture-risk assessment, the role of Vitamin D and calcium, and to provide follow-up to those not on treatment at baseline to ensure they follow through with their PCP on suggestions made in clinic. In this model, much of the OP-related action needs to be taken by the PCP and the patients themselves (ie, investigation, intervention, and compliance).^\[[@R9],[@R10]\]^ Coordinators are hired and trained centrally through Osteoporosis Canada to provide consistent, up-to-date information. Outcomes for this program have been reported and suggest up to 50% of patients will go on to have BMD testing, and 21% initiate prescription pharmacotherapy,^\[[@R34]\]^ reflecting advances over previous estimates of \<10% to 20% having any discussion of bone health with their health care providers.

All sites had approval from their respective research ethics board for research use of the data in consenting patients. This specific analysis was also approved by the research ethics board of the senior investigator\'s (DEB) home institution, St. Michael\'s Hospital (REB\# 08--304C).

2.2. Study design
-----------------

This study made use of administrative health data for all insured Ontarians which are maintained at the Institute for Clinical Evaluative Sciences (ICES) in Toronto. ICES is a prescribed entity funded through the Ministry of Health and Long Term Care (single insurer in the province) and holding linked sociodemographic and health information for insured health events. It supports linked data across billing data for physicians and emergency room visits, diagnostic testing billings, hospital separations and, in those over the age of 65, prescription drug billings covered by the Ontario Drug Benefits Program. All persons eligible for universal health care in Ontario have health care expenses and activity tracked in these databases. The various data are linked across sources and longitudinally and are maintained at ICES. Data housed at ICES are widely used in health services research and are considered to be of high quality.^\[[@R35],[@R36]\]^

Fragility fracture cases from January 2002 (5 years, 20 quarters) before the program to March 2010 (3 years after the start of the program) were identified using the Public Health Agency of Canada\'s (PHAC) case definition for a fragility fracture. This definition sought diagnostics codes (ICD9-CM and ICD10) for humerus, forearm, hip, spine, and pelvis fractures on billing data or hospital discharge records and restricts cases to those over age of 50^\[[@R36]\]^ with no similar fracture codes billed to that person\'s file in the 6 months before that identification (ie, thus defining a "new" fracture). If billing codes related to a similar fracture were found in the past 6 months, we assumed the current episode of care was for the previous fracture.^\[[@R36]\]^ The PHAC case definition relies on the fracture type and age as being likely fragility fractures and does not specify low trauma etiology. This might attenuate intervention effects for programs like ours by including low and high trauma fractures; however, its universal application across the population makes it the only means to compare before and after the program\'s initiation in intervention hospitals or control.

Cases meeting PHAC fracture types were identified and restricted to those seen by orthopedic surgeons in the first 30 days post fracture, and seen at a moderate or high fragility fracture volume hospital (determined by the Ministry of Health and Long Term Care as having \>350 fragility fracture cases per year). The cases were restricted to those over age of 50 and then separated into control and intervention hospitals based on whether that hospital had been assigned 1 of the 20 coordinators by the FCSP (intervention). The start time for the intervention varied over the ramp up of the program, so the individual start date was assigned time zero for each site and quarters defined as 3-month intervals before and after that date. Control hospitals had no such start date, and were assigned a start date by randomly selecting (without replacement) from the start dates of intervention hospitals. Quarters were then assigned again before and after that date. Each individual was then followed for outcome indicators for 1 year after the quarter in which their fracture visit occurred.

2.3. Administrative outcomes
----------------------------

### 2.3.1. Primary outcome: bone mineral density testing within 1 year of fracture

BMD testing was considered the primary outcome, as it is the most universal marker (ie, includes all eligible age groups, whereas medication use is only for those over 65) of post-fracture OP activity in our cohort.^\[[@R35]\]^ Billing for BMD testing in those eligible for BMD was calculated to create the primary outcome rate. Those who had a BMD test in the year before their fracture were not eligible for retesting, as their previous results would be considered adequate for fracture-risk assessment.

### 2.3.2. Secondary outcome: treatment initiation within 1 year of screening in those over 65 years of age

Treatment initiation was defined as the filling of a prescription for a bone-sparing agent in the year after a fragility fracture (ie, the first clinic visit after fracture).^\[[@R35]\]^ Those who had filled a prescription in the year before the fracture were excluded from the analysis on treatment initiation, as they were considered previously treated and would not reflect program impact. Medication billing was available for those 66 years and older, as all Ontarians 65 years and older are eligible for free prescription medications, including bone-sparing medication, through the Ontario Drug Benefits Program. In this analysis, we could therefore only include persons 66 years and older at time of fracture, to permit examination of the year before fracture to exclude those taking bone-sparing medication before the index fracture. Medications considered in this definition were: alendronate, risedronate, calcitonin, etidronate, teriparatide, and zoledronic acid.

### 2.3.3. Secondary outcome: persistence with taking medication

Persistence with medication was measured by calculating the proportion of days covered (PDC) by the drug prescriptions that were filled^\[[@R37],[@R38]\]^ as an indicator of medication taking behavior or adherence. A PDC threshold of at least 80% (ie, the person filled enough prescriptions to comply with 80% of the usual dose)^\[[@R37],[@R38]\]^ was required, as this has been shown to be the acceptable threshold for fracture prevention benefit.^\[[@R39]\]^ Compliance was calculated as the proportion of patients who initiated care in the year following their fracture who met the PDC threshold. We also report a lower threshold, PDC-50 (50% rather than 80%).

2.4. Analysis
-------------

### 2.4.1. Description of sample

The sample capture and characteristics were described using descriptive statistics.

### 2.4.2. Description of outcome rates

The sample description and the rates of the target outcomes described for all PHAC fracture cases seen in the control and intervention hospitals before and after program implementation were calculated and summarized. The numerator and denominator were defined only by those eligible for that outcome in that 1-year observation window. Thus, follow-up of an individual was censored at the 1-year post-screening visit to prevent late events (ie, BMD testing beyond 1 year) from favorably influencing rates.

### 2.4.3. Interrupted time series

To test for a shift in trends, we employed an interrupted time series analysis---a study design used to evaluate the longitudinal effects of interventions, through regression modelling. Since the interrupted time series is well suited for evaluation of effectiveness of population-level health interventions that have been implemented at a clearly defined point in time,^\[[@R40]\]^ we employed this study design to evaluate whether the program led to increased BMD testing, treatment initiation and persistence in the intervention group when compared with the control hospitals. Interventional autoregressive, integrated moving average (ARIMA) models were used to examine the impact of program initiation on rates of outcomes.^\[[@R41],[@R42]\]^ Models were represented by their structural parameters and the best ARIMA model was selected based on the Schwarz-Bayesian criterion.^\[[@R43]--[@R45]\]^ Initial model specification was guided by visual inspection of correlograms, and ramp intervention functions were used to allow for more gradual intervention uptake. To test the appropriateness of model assumptions, we examined the autocorrelation, partial autocorrelation, and inverse autocorrelation functions. We performed the augmented Dickey-Fuller test to test for stationarity and examined the Ljung-Box χ^2^ statistic at various lags to assess autocorrelation.

The anticipated shape of the impact of the intervention was either an immediate or delayed, yet sustained, higher rate of outcome after the intervention compared with before. The control hospitals were expected to experience no such change in trend but to continue as per pre-intervention trends. Analysis was carried out in SAS 9.3 (Cary, NC: SAS Institute).

3. Results
==========

A cohort flowchart can be found in Figure [1](#F1){ref-type="fig"}. A final set of 147,071 cases were identified as having met the PHAC operational case definition for fragility fracture, age, and site criteria and had a visit date for the fracture before April 10, 2010 and were used in the analysis. At the intervention hospitals 109,173 fractures met the PHAC definition: 69,856 before the intervention and 39,317 after (some of which would have been in our program but not all). The control hospitals had 24,676 fractures before the program began and 13,222 fractures in the post-intervention period.

![Flowchart depicting creation of the dataset from administrative health data used in this time series analysis.](medi-96-e9012-g001){#F1}

The demographic information is summarized in Table [1](#T1){ref-type="table"}. Comparison of the pre-intervention group at the intervention hospitals and control hospitals demonstrated considerable similarities in terms of age, gender, and breakdown of fracture type.

###### 

Description of samples used in the interrupted time series analyses (control and intervention hospitals before and after implementation).

![](medi-96-e9012-g002)

3.1. Time series analysis
-------------------------

Table [2](#T2){ref-type="table"} summarizes the rates and their statistical significance for OP outcomes in the cases identified for the interrupted time series analysis before and after program initiation at hospitals with and without coordinators (intervention and control, respectively).

###### 

Observed outcome rates for pre- and post-intervention samples at intervention and control hospitals.

![](medi-96-e9012-g003)

3.2. Primary outcome
--------------------

Average BMD testing rates increased significantly among intervention hospitals (from 17.0% before program implementation to 20.9% following implementation; *P* \< .01, Table [2](#T2){ref-type="table"}). The BMD testing rates at the control hospitals were stable at 14.9% (*P* = .33). This is depicted graphically in Figure [2](#F2){ref-type="fig"}.

![Graphical depiction of trends for outcomes, divided into pre- and post-implementation phases (vertical line). Main lines (continuing before and after implementation) depict overall trends for intervention sites (blue) and control sites (red boxes).](medi-96-e9012-g004){#F2}

3.3. Secondary outcomes
-----------------------

Treatment initiation (pharmacotherapy dispensing in those over 65) showed statistically significant increases in intervention hospital (*P* \< .02) moving from 21.6% pre-implementation to 24.0% post-implementation, but there was no change in the control hospitals (17.5% and 18.5%, respectively, *P* = .27). Medication persistence estimated by the PDC of either 80% or 50% declined in all groups from pre- to post-intervention period. Persistence in medication taking among intervention hospital cases dropped from 59.9% pre-intervention to 56.4% post-intervention (*P* = .02 at PDC50). At the PDC 80, the rates decreased from 45.8% to 40.01% (*P* \< .001). In control hospitals, a larger decrease in persistence (PDC 50) was found: 62.3% to 54.2%, *P* \< .01 or 47.6% to 38.5% (*P* \< .01) using a PDC-80 threshold.

4. Discussion
=============

Interrupted time series analysis demonstrated a statistically significant increase in BMD testing rates in persons 50 years and older who had sustained a low-trauma fracture after the implementation of a province-wide FCSP compared with before implementation. Further, similar changes were not found in hospitals that were not participating in the program over the same time frame. Higher rates of treatment initiation were also observed following the program implementation in intervention over control hospitals. Persistence with medication taking in the year following initiation declined in both groups in the post-implementation period, and this should be the focus of further inquiry as to whether it is an artifact of media attention leading to discontinuation^\[[@R14]\]^ or changes in the dispensing practices biasing toward lower adherence rates.^\[[@R46]\]^ Treatment initiation rates were higher in the intervention hospitals (24.0%) than the control hospitals (18.5%) after the program started. However, these levels continue to be below what we have seen achieved in clinical trials, and what we might expect as the target in this higher risk group. One might expect a lower rate in an evaluation of a widespread implementation such as our program compared with a randomized trial, but ideal levels should always be the aim.

The program described in this paper would be considered a type C (education, targeted communication with providers) in the review by Ganda and this was associated with an estimated 30% absolute increase in testing rates---we found a lower rate when looking at the average for the interrupted time series analysis, but a comparable rate when, like Ganda,^\[[@R18]\]^ we described only the confirmed low-trauma fracture participants in this data (43% testing).

5. Strengths
============

Interrupted time series analyses are considered the most robust quasi-experimental design for inferring causality between intervention and outcome in the absence of a randomized controlled trial.^\[[@R40],[@R47],[@R48]\]^ Our ability to also examine a complementary comparison group strengthens our conclusion that the outcomes we observed were not due to a competing shift in provincial practices, or secular advances in guideline implementation,^\[[@R49],[@R50]\]^ or other facets of the Ontario Osteoporosis Strategy itself---for example, public and health care professional education and efforts in rehabilitation and long-term care.^\[[@R14],[@R33]\]^

A key feature in the quality of an interrupted time series analysis is the independent, unbiased ascertainment of outcomes,^\[[@R48]\]^ and in our situation independence from the embedded coordinator him/herself. We used administrative data to allow greater objectivity across all subjects and less influence on outcome in those who were seen by the coordinator for follow-up information. The primary outcome was BMD testing billings, because they were available for all patients in the cohort (ie, not limited to those over age 66 years as was the case for medication initiation and persistence outcomes) and were recorded in the administrative health billings consistently over the study duration. An amendment to the government\'s funding of BMD testing came into place in 2007 in an effort to curb overuse in low-risk patients. It was not intended to impact the testing of these higher-risk patients, and we believe that if it did, it would have done so equally in the intervention and control hospitals. BMD testing was therefore considered the most universal indicator of OP-related activity after a fragility fracture.

Ramsay et al^\[[@R48]\]^ suggest a set of 8 criteria for a high quality, interrupted time series analysis. Our study meets these criteria, with the exception that the observed impact of our intervention was more immediate and sustained than anticipated in our a priori hypothesis.

6. Limitations
==============

There were 2 limitations to this study that should be acknowledged. First, the use of the PHAC case definition, though well accepted and recommended,^\[[@R36]\]^ focuses on accurate coding for a probable or likely fragility fractures (type of fracture type and age), but it cannot ascertain the low-trauma nature of the fracture. All of our groups could therefore be a mix of high and low trauma. This would suggest that the focus of our message is on the trend, the shift that we observed and it significance, recognizing the actual point estimates could be attenuated by the inclusion of people who may have had high-trauma fractures (and would not be seen in our program) or indeed people whom the coordinators missed due to their being part time at each site. For the interrupted time series analysis the case definition had to be the same across all groups and we chose the PHAC as recommended for chronic disease surveillance in Canada.^\[[@R36]\]^ The significance of our findings despite this attenuation builds confidence in our results.

A second limitation is the potential that there were uncontrolled biases in this analysis. Interrupted time series assumes populations of independent individuals, but there could have been clustering within hospitals in both our intervention and our control sites. Because we had so many sites, and we had control sites showing no advances in testing and treatment rates, we felt confident that the impact of any within hospital trends was not the cause of our findings.

Future research will continue to monitor the impact of the Ontario FCSP as changes are made. Recently a shift was made to allow the coordinators to order and book BMD testing allowing fracture-risk assessments to be communicated back to the PCP bringing more information to that visit. Future research can test for further impact of that program change. This shift will also allow risk stratified analyses based on the access to BMD test results and fracture-risk assessments that will be linked to the administrative data at ICES and provide more specific need-based analyses.

7. Conclusions
==============

This study evaluated the impact of the implementation of a program designed to reduce a gap between clinical practice guidelines and front-line OP care following a fragility fracture. The program was implemented across 37 different hospitals in the province, reflecting some of the busiest fracture clinics in that publically funded health system. We demonstrated a positive, statistically significant impact of a coordinator, who acts as case finder, educator, and facilitator of bone-health screening and treatment in the fracture clinic setting, on BMD testing and OP treatment initiation. This study adds support to the growing body of knowledge on the effectiveness of fracture liaison service coordinator models^\[[@R21]--[@R24],[@R28]\]^ and is the first to use an interrupted time series analysis to evaluate the impact.
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